Living with hemorrhagic proctocolitis can be a distressing and isolating experience. The combination of rectal bleeding, urgent bowel movements, and abdominal pain often creates significant anxiety around daily activities and social engagements. Beyond the physical discomfort, the unpredictability of symptoms can make planning for work or travel difficult. Treatment is essential to not only alleviate these disruptive symptoms but also to heal the inflamed tissue in the rectum and colon, preventing long-term damage and reducing the risk of severe complications. 

Because the severity of inflammation and the extent of the disease vary widely among individuals, there is no single treatment plan that works for everyone. Some people experience mild, intermittent symptoms, while others face chronic challenges that require more aggressive therapy. Doctors tailor medication choices based on the specific cause whether it is an autoimmune reaction like ulcerative colitis or an infection and how well the patient tolerates different therapies (National Institute of Diabetes and Digestive and Kidney Diseases, 2024). 

Overview of treatment options for Hemorrhagic Proctocolitis 

The primary goals of treatment are to stop rectal bleeding, reduce inflammation in the bowel lining, and achieve a state of remission where symptoms are absent. Effective management helps the mucosal lining of the colon heal, which is crucial for preventing future flare-ups and complications such as anemia or dehydration. 

Medication is the mainstay of treatment for most forms of hemorrhagic proctocolitis, particularly those related to chronic inflammatory bowel disease. In acute infectious cases, treatment may be supportive, focusing on hydration while the body clears the pathogen, though antibiotics are sometimes necessary. For chronic cases, long-term maintenance medication is typically required. Surgical procedures are generally reserved for severe cases that do not respond to medical therapy or when complications like severe bleeding occur. 

Medications used for Hemorrhagic Proctocolitis 

Doctors prescribe specific drug classes to target inflammation and control the immune system’s response in the digestive tract. 

Aminosalicylates: These are often the first line of defense for mild to moderate cases. Drugs such as mesalamine and sulfasalazine contain 5-aminosalicylic acid (5-ASA), which helps reduce inflammation directly in the lining of the gut. They are available in oral pills or as rectal suppositories and enemas, which are particularly effective for reaching the rectum and lower colon. Clinical experience suggests that topical rectal therapies are highly effective for patients with inflammation limited to the lower bowel. 

Corticosteroids: When symptoms are severe or do not respond to aminosalicylates, doctors may prescribe corticosteroids like prednisone or budesonide. These are powerful, fast-acting anti-inflammatory drugs used to bring active flare-ups under control. They are typically used for short periods because long-term use carries the risk of significant side effects. 

Immunomodulators and Biologics: For patients with moderate to severe disease that does not improve with other treatments, stronger medications may be necessary. Immunomodulators like azathioprine work to calm the immune system over time. Biologics, such as infliximab or adalimumab, are targeted therapies that block specific proteins that cause inflammation. These are often administered via injection or IV infusion. 

How these medications work 

The medications used to treat this condition primarily function by interrupting the cycle of inflammation that damages the intestinal wall. 

Aminosalicylates work topically on the gut lining like a soothing cream, reducing inflammatory chemicals like prostaglandins in the colon tissue. 

Corticosteroids mimic natural cortisol, suppressing the entire immune system to rapidly reduce colon swelling, redness, and bleeding, allowing tissue repair. 

Biologics are precise, targeting specific immune pathways and neutralizing proteins that signal the body to attack its gut tissue, thus preventing inflammation. 

Side effects and safety considerations 

While these treatments are effective, they come with safety considerations that require monitoring. 

Aminosalicylates are usually well-tolerated, though they can cause headache, nausea, or abdominal pain. Rare kidney issues mean periodic function tests may be advised. 

Corticosteroids often cause side effects like weight gain, mood swings, higher blood pressure, and insomnia. They are tapered quickly once a flare is controlled due to risks of bone weakening and infection. 

Immunomodulators and biologics suppress the immune system, slightly increasing infection risk. Patients must report fever or persistent illness immediately. Pregnant or planning women should consult specialists about medication safety. 

Since everyone’s experience with the condition and its treatments can vary, working closely with a qualified healthcare provider helps ensure safe and effective care. 

References 

  1. National Institute of Diabetes and Digestive and Kidney Diseases. https://www.niddk.nih.gov 
  1. Mayo Clinic. https://www.mayoclinic.org 
  1. Crohn’s & Colitis Foundation. https://www.crohnscolitisfoundation.org 
  1. American Gastroenterological Association. https://gastro.org 

Medications for Hemorrhagic Proctocolitis

These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Hemorrhagic Proctocolitis.

Found 25 Approved Drugs for Hemorrhagic Proctocolitis

Infliximab

Brand Names
Zymfentra, Avsola, Inflectra, Remicade, Renflexis

Infliximab

Brand Names
Zymfentra, Avsola, Inflectra, Remicade, Renflexis
ZYMFENTRA is a tumor necrosis factor (TNF) blocker indicated in adults for maintenance treatment of: moderately to severely active ulcerative colitis following treatment with an infliximab product administered intravenously. ( 1 ) moderately to severely active Crohn’s disease following treatment with an infliximab products administered intraneously. ( 1 ) ZYMFENTRA is indicated in adults for maintenance treatment of: moderately to severely active ulcerative colitis following treatment with an infliximab product administered intravenously. moderately to severely active Crohn's disease following treatment with an infliximab product administered intravetnously.

Mesalamine

Brand Names
Pentasa, Canasa, Apriso, Lialda, sfRowasa Sulfite-Free, Rowasa

Mesalamine

Brand Names
Pentasa, Canasa, Apriso, Lialda, sfRowasa Sulfite-Free, Rowasa
Mesalamine delayed-release tablets are indicated for the: induction and maintenance of remission in adult patients with mildly to moderately active ulcerative colitis. Pediatric use information is approved for Takeda Pharmaceuticals U.S.A., Inc.'s LIALDA (mesalamine) delayed-release tablets. However, due to Takeda Pharmaceuticals U.S.A., Inc.'s marketing exclusivity rights, this drug product is not labeled with that information. Mesalamine delayed-release tablets are an aminosalicylate indicated for the: induction and maintenance of remission in adult patients with mildly to moderately active ulcerative colitis. ( 1 )

Entyvio

Generic Name
Vedolizumab

Entyvio

Generic Name
Vedolizumab
ENTYVIO is indicated in adults for the treatment of: moderately to severely active ulcerative colitis (UC). moderately to severely active Crohn's disease (CD). ENTYVIO is an integrin receptor antagonist indicated in adults for the treatment of: moderately to severely active ulcerative colitis (UC). ( 1 ) moderately to severely active Crohn's disease (CD). ( 1 )

Sulfasalazine

Brand Names
Azulfidine, Azulfidine EN-tabs

Sulfasalazine

Brand Names
Azulfidine, Azulfidine EN-tabs
Sulfasalazine delayed release tablets are indicated: a) in the treatment of mild to moderate ulcerative colitis, and as adjunctive therapy in severe ulcerative colitis; b) for the prolongation of the remission period between acute attacks of ulcerative colitis; c) in the treatment of patients with rheumatoid arthritis who have responded inadequately to salicylates or other nonsteroidal anti-inflammatory drugs (e.g., an insufficient therapeutic response to, or intolerance of, an adequate trial of full doses of one or more nonsteroidal anti-inflammatory drugs); and d) in the treatment of pediatric patients with polyarticular-course 1 juvenile rheumatoid arthritis who have responded inadequately to salicylates or other nonsteroidal anti-inflammatory drugs. Sulfasalazine delayed release tablets are particularly indicated in patients with ulcerative colitis who cannot take uncoated sulfasalazine tablets because of gastrointestinal intolerance, and in whom there is evidence that this intolerance is not primarily the result of high blood levels of sulfapyridine and its metabolites, e.g., patients experiencing nausea and vomiting with the first few doses of the drug, or patients in whom a reduction in dosage does not alleviate the adverse gastrointestinal effects. In patients with rheumatoid arthritis or juvenile rheumatoid arthritis, rest and physiotherapy as indicated should be continued. Unlike anti-inflammatory drugs, sulfasalazine delayed release tablets do not produce an immediate response. Concurrent treatment with analgesics and/or nonsteroidal anti-inflammatory drugs is recommended at least until the effect of sulfasalazine delayed release tablets is apparent.

Ustekinumab

Brand Names
Steqeyma, Pyzchiva, Stelara, Ustekinumab-TTWE, Yesintek, Wezlana, Otulfi, Imuldosa

Ustekinumab

Brand Names
Steqeyma, Pyzchiva, Stelara, Ustekinumab-TTWE, Yesintek, Wezlana, Otulfi, Imuldosa
PYZCHIVA is a human interleukin-12 and -23 antagonist indicated for the treatment of: Adult patients with: moderate to severe plaque psoriasis (PsO) who are candidates for phototherapy or systemic therapy.
Showing 1-5 of 25
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances